Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.
about
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyEpigenetic regulators and their impact on therapy in acute myeloid leukemiaMolecular prognostic factors in cytogenetically normal acute myeloid leukemiaTET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaRUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemiasGAS6 expression identifies high-risk adult AML patients: potential implications for therapyPrognostic impact of RAS mutations in patients with myelodysplastic syndrome.IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cellsPrognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemiaClinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemiaDNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patientsIs it important to decipher the heterogeneity of "normal karyotype AML"?Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.Epigenetics in acute myeloid leukemia.Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia.SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.Older patients with acute myeloid leukemia.Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics.Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?Mixed lineage leukemia protein in normal and leukemic stem cells.Chromatin modifiers and the promise of epigenetic therapy in acute leukemiaAllogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia.Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy.MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition.Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse.Molecular predictors of post-transplant survival in acute myeloid leukemia.Emerging molecular predictive and prognostic factors in acute myeloid leukemia.The initial level of MLL-partial tandem duplication affects the clinical outcomes in patients with acute myeloid leukemia.
P2860
Q24643738-E5A4109F-7328-4AB6-B29E-EECE22D10102Q26765402-8B62DAF8-7813-4C58-BE1D-825FF724B5A0Q26998811-B01BA9A2-3A97-470D-9ED7-C8042D48A6A6Q27851621-8CF06FE8-DDCD-4EF7-B87F-B5A610EF3C8DQ27851679-89A4430B-7424-46E7-AC23-0D6FE36BB0DDQ27851713-58736D2D-7EE2-42E1-92FA-74F691A23626Q27851839-5081B8A1-081F-4698-81C3-2FFC45D03E1AQ28594733-5C458BDB-ED7A-4571-83E2-CE1D6B793E71Q33717707-3C2D7FE3-5ED7-4153-BA9A-9900BBAAB6FFQ33871210-28838CBE-C293-4063-BF15-91145596D579Q33897586-AD9C18C1-62E1-4094-A1E6-CD3E6AC7A6DDQ34047867-B89A7629-B092-462E-98F0-6932C79E6FABQ34477821-99D678F3-DDAA-4B22-8639-5147678AB9E3Q35152173-A2D81899-A7C5-49BB-BE14-B4AC97A2C971Q35265946-672B134C-BA9F-439F-B7B4-CB90D8C606E9Q36545112-ACFE45BC-257F-4AA9-B691-28788D76AF9BQ36591431-F2FE91B6-9E72-450C-82A1-624D51C51295Q36843784-F6BE479E-511B-491C-9B16-821D45004846Q37065843-95A9457F-DE06-4AC9-9B9B-40FA82EF3AACQ37110802-96F7DB54-1472-4FDD-B724-DD37200F0B6AQ37119445-3AE4B27B-F79F-4A7E-AC59-E17E4B50F905Q37240566-D1439602-3F61-4041-B824-D547C5E5251DQ37349410-8785A0C5-593B-4087-AA51-3326A6A7B691Q37394708-8F6ED8FF-C2F9-4ECA-BA42-E3FC1FC0CA29Q37412298-AC7F75BB-85F8-4EAC-A19F-EA6DC0214688Q37679943-3C10000B-88D0-459D-8F6A-C14C940F37D4Q37810969-B1EE38AD-B622-4269-BAF9-5E3E3C7C23D5Q37954583-64067975-6370-478F-BFF3-527677D4EDF6Q38044773-20396FE5-3659-406A-8721-E8F8F800AC43Q38100107-D4B775A4-B4B1-49CE-B7E2-ACA2B00B4FC0Q38194444-F1F5F503-D7EC-4CAF-99C8-87A39F13229CQ38199056-9D252C7D-B2E9-45DF-80BE-D5F925288731Q38703904-68A31279-2D85-4966-B552-E5575FF8E7F1Q38860767-5522254E-EA90-4313-BB6A-B8FEC8FF8E6AQ40147710-384499D0-51D9-40A6-9210-6516CA4DEF86Q42573850-6C9A166D-77C4-4688-8C95-E5E704445C48Q42724137-3F54C613-2CB4-492B-A76F-81023FD9ECD7Q47256283-6FBC836C-3377-4E3D-9387-64A3FE1A54E0Q47670541-527932BB-5317-4967-8238-54A8B2BBF6C1Q48343112-13E6C2F6-D046-4377-84CF-787C2A8C13A6
P2860
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Long-term disease-free survivo ...... er and Leukemia Group B study.
@ast
Long-term disease-free survivo ...... er and Leukemia Group B study.
@en
type
label
Long-term disease-free survivo ...... er and Leukemia Group B study.
@ast
Long-term disease-free survivo ...... er and Leukemia Group B study.
@en
prefLabel
Long-term disease-free survivo ...... er and Leukemia Group B study.
@ast
Long-term disease-free survivo ...... er and Leukemia Group B study.
@en
P2093
P2860
P50
P1433
P1476
Long-term disease-free survivo ...... er and Leukemia Group B study.
@en
P2093
Amy S Ruppert
Andrew J Carroll
Bayard L Powell
Christian Langer
Claudia D Baldus
Jonathan E Kolitz
Michael A Caligiuri
Peter Paschka
Susan P Whitman
P2860
P304
P356
10.1182/BLOOD-2007-01-069831
P407
P577
2007-03-06T00:00:00Z